Potassium binders are medications that bind potassium ions in the gastrointestinal tract, thereby preventing its intestinal absorption. This category formerly consisted solely of polystyrene sulfonate, a polyanionic resin attached to a cation, administered either orally or by retention enema to patients who are at risk of developing hyperkalaemia (abnormal high serum potassium levels). Newer drugs include: another polyanionic polymer, patiromer, which exchanges calcium for potassium; and Sodium zirconium cyclosilicate crystals, which exchange sodium for potassium
Increased serum potassium levels are a condition likely to occur in patients with chronic kidney disease in advanced stages.
Clinical use edit
Potassium, the most abundant intracellular cation, is essential for life. An adequate gradient of potassium across the cell membrane is necessary in order to enable excitability of cell membranes. This is particularly important for nerve and muscle function. In humans, mainly the kidneys are responsible for the regulation of serum potassium levels by excreting excess potassium via the urine. As kidney failure progresses, with a consequent decline of excretory function, potassium is likely to accumulate with probable harmful effects on the cellular membrane potential and cardiac arrhythmias as the primary symptom.[1] If the physiological potassium blood level of between 3.8 mmol/L and 5.2 mmol/L is exceeded, hyperkalaemia is diagnosed.[2] The mainstay of the treatment for chronic kidney disease patients is potassium removal through the dialysis procedure. However, dietary restrictions and pharmaceutical therapy with potassium binders are important complementary treatment options.
Mechanism of action edit
In general, potassium binders are artificial polyanionic resins that exchange bound cations (Ca2+ or Na+) for potassium ions in the distal large intestine.[3] After exchange, the released cation and potassium adhering to the resin are excreted with the faeces. This mechanism prevents intestinal absorption of alimentary potassium ions and thereby reduces serum potassium levels. There are two major classes of binders, differentiated by the cation attached to the resin in the original condition. Calcium resins release calcium ions in exchange for potassium ions, whereas sodium resins release sodium.
Side effects edit
Hypokalemia, hypomagnesaemia, nausea or vomiting are side effects commonly seen when polystyrene resins are used. Cases of colonic necrosis have been reported, particularly when sodium polystyrene sulfonate was used in combination with the laxative sorbitol. Additionally, electrolyte disturbances, systemic alkalosis or gastric irritation may occur. Furthermore, anorexia, nausea, vomiting or constipation as well as diarrhea have been recorded if high doses were applied.[4][5]
Potassium-binding resins edit
- Polystyrene sulfonates
- Calcium polystyrene sulfonate (e.g. Sorbisterit, Ca-Resonium)
- Sodium polystyrene sulfonate (e.g. Kayexalate, Anti-Kalium-NA)
References edit
- ^ MedlinePlus Encyclopedia: High potassium level
- ^ Hagemann, O., Normal Serum Potassium Levels, URL: http://www.laborlexikon.de/Lexikon/Infoframe/k/Kalium_Serum.htm; Retrieved 21 January 2010.
- ^ Hyperkalemia~treatment at eMedicine
- ^ Sorbisterit – Summary of Product Characteristics; Retrieved: 21 January 2010.[full citation needed]
- ^ U.S. National Library of Medicine. URL: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=11425; Retrieved: 21 January 2010
External links edit
- Buysse, Jerry M; Huang, I-Zu; Pitt, Bertram (2012). "PEARL-HF: prevention of hyperkalemia in patients with heart failure using a novel polymeric potassium binder, RLY5016". Future Cardiology. 8 (1): 17–28. doi:10.2217/fca.11.71. PMID 22185443.
- van der Meer, P.; van Veldhuisen, D. J. (2011). "To bind or not to bind: potassium-lowering drugs in heart failure". European Heart Journal. 32 (7): 791–2. doi:10.1093/eurheartj/ehr058. PMID 21383002.
- Hyperkalemia in Emergency Medicine at eMedicine
- Potassium and your CKD Diet - kidney.org